ACE 2016
Alternative Names: ACE-2016Latest Information Update: 20 Dec 2024
At a glance
- Originator Acepodia
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 Aug 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Taiwan and US (Parenteral) (NCT06415487)
- 04 Feb 2024 Acepodia plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease) in USA (parenteral) in second half of 2024 (NCT06415487)
- 04 Feb 2024 US FDA approves IND application for ACE 2016 in Solid tumours